March 2015. Volume 11. Number 1

Tacrolimus, ¿qué lugar ocupa en el tratamiento de la dermatitis atópica?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

EP | Evidentia Praxis

Authors: Orejón de Luna G1, Fernández Rodríguez M2.
1CS General Ricardos. Madrid. España.
2CS Potes. Madrid. España.
Correspondence: Gloria Orejón de Luna. Email: gloriaglo04@gmail.com
Reception date: 17/11/2014
Acceptance date: 03/02/2014
Publication date: 11/02/2015

Abstract

EP | Evidentia Praxis

Authors: Orejón de Luna G1, Fernández Rodríguez M2.
1CS General Ricardos. Madrid. España.
2CS Potes. Madrid. España.
Correspondence: Gloria Orejón de Luna. Email: gloriaglo04@gmail.com
Reception date: 17/11/2014
Acceptance date: 03/02/2014
Publication date: 11/02/2015

Sorry, there is no English version for this item.

How to cite this article

Orejón de Luna G, Fernández Rodríguez M. Tacrolimus, ¿qué lugar ocupa en el tratamiento de la dermatitis atópica? Evid Pediatr. 2015;11:2.

References

  1. Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62:184.
  2. Doss N, Kamoun MR, Dubertret L, Cambazard F,Remitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate to severe atopic dermatitis: evidence from a randomized, double-blind non inferiority trial vs fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21:321.
  3. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-46.
  4. Reitamo JH, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554-62.
  5. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21:144-56.
  6. Svensson A, Chambers C, Gånemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27:1395-406.
  7. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, HunterJJ, et al. The UK working party’s diagnostic criteria for atopicdermatitis. Br J Dermatolol. 1994;131:383-96.
  8. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eccema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11-8.
  9. Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010; 21:34-44.
  10. Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008;122:e1210-8.
  11. Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3 times weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008; 58:990-9.
  12. Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43:1956-63.
  13. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163-78.
11/02/2015

Linked Comment